Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1989-5-12
|
pubmed:abstractText |
The efficacy and safety of lovastatin as a hypolipidemic agent were evaluated in ten adult patients with secondary hypercholesterolemia due to proteinuria (greater than 2 g/d) and (in seven patients) concurrent corticosteroid therapy. Patients were on a low-cholesterol diet throughout the study. After a 4-week baseline period, patients were randomized to receive either placebo or 10 mg lovastatin twice daily for a period of 6 weeks. The dose of lovastatin was increased to 20 mg twice daily for 6 weeks, and 40 mg twice daily for 6 weeks in the latter group. Those patients who received placebo for the first 6 weeks subsequently received 10, 20, and 40 mg of lovastatin twice daily in a stepped dose regimen, with each dose given for 6 weeks. Lovastatin was well tolerated by all patients and none withdrew from the study. Baseline plasma cholesterol concentrations (390 +/- 20 mg/dL; mean +/- SEM) decreased 22% (P less than 0.003) at the lowest dose of 10 mg twice daily, 27% at 20 mg twice daily, and 33% at 40 mg twice daily. Baseline plasma triglycerides decreased by 25% (P less than 0.05) at the highest dosage. Concentrations of low-density lipoprotein (LDL) cholesterol fell by 29%, 34%, and 45% on doses of 10, 20, and 40 mg of lovastatin twice daily. Concentrations of high-density lipoprotein (HDL) cholesterol increased slightly. Serum creatinine concentrations and proteinuria were not affected by lovastatin therapy. We conclude that lovastatin was a well-tolerated and extremely effective hypocholesterolemic agent in patients with persistent secondary hypercholesterolemia associated with proteinuria or proteinuria and concurrent corticosteroid therapy.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenal Cortex Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, Dietary,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, HDL,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Lovastatin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0272-6386
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
13
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
312-20
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2650539-Adrenal Cortex Hormones,
pubmed-meshheading:2650539-Adult,
pubmed-meshheading:2650539-Cholesterol, Dietary,
pubmed-meshheading:2650539-Cholesterol, HDL,
pubmed-meshheading:2650539-Cholesterol, LDL,
pubmed-meshheading:2650539-Clinical Trials as Topic,
pubmed-meshheading:2650539-Female,
pubmed-meshheading:2650539-Humans,
pubmed-meshheading:2650539-Hypercholesterolemia,
pubmed-meshheading:2650539-Lovastatin,
pubmed-meshheading:2650539-Male,
pubmed-meshheading:2650539-Middle Aged,
pubmed-meshheading:2650539-Nephrotic Syndrome,
pubmed-meshheading:2650539-Proteinuria,
pubmed-meshheading:2650539-Random Allocation
|
pubmed:year |
1989
|
pubmed:articleTitle |
Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria.
|
pubmed:affiliation |
Department of Medicine, Oregon Health Sciences University, Portland 97201.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|